Evaluation of HCV-related liver fibrosis post-successful DAA therapy

Ehsan, Nermine; Sweed, Dina; Elsabaawy, Maha

doi:10.1186/s43066-021-00129-0

Cited by 6 publications

(6 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Liver fibrosis is a considerable complication of HCV infection and can progress to cirrhosis, liver failure, and HCC. 20 The presence of fibrosis affects the development of hepatocellular carcinoma being a dynamic process that involves cross-talk between hepatocytes, HSCs, sinusoidal endothelial cells and both resident and infiltrating immune cells; through the influence of cytokines, and chemokines; and mitochondria and metabolic changes in hepatic stellate cells modulating this process. 16 Finally, DEPDC5 (rs1012068) could be a valuable indicator in diagnosing the progression of liver disease to HCC risk related HCV patients.…”

Section: Discussionmentioning

confidence: 99%

Disheveled EGL-10 and pleckstrin domain-containing 5 rs1012068 T/G gene polymorphism among Egyptian chronic HCV-infected patients: disease progression and related complications

Farhan

Abougabal

Gaber

et al. 2022

EJI

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection related complications including fibrosis, cirrhosis and hepatocellular carcinoma (HCC) are influenced by host genetic factors. Identification of emerging host genetic variations is of promising value. Disheveled EGL-10 and pleckstrin domain-containing 5 (DEPDC5) rs1012068 T/G gene polymorphism has been implicated in liver disease. This study aimed to assess DEPDC5 rs1012068 T/G gene polymorphism with disease progression and related complications among Egyptian patients with chronic HCV infection. Sixty chronic HCV-infected patients and 60 apparently healthy controls were recruited in this study. Patients were classified into 20 with liver fibrosis, 20 with liver cirrhosis and 20 with HCC; all recruited from Outpatients Clinic and Tropical Medicine Inpatient Department, Faculty of Medicine, Beni-Suef University Hospital. DEPDC5 rs1012068 T/G gene polymorphism was assayed by real time-polymerase chain reaction (RT-PCR) TaqMan allelic discrimination. DEPDC5 rs1012068 GG genotype and G allele variants showed statistically significant higher frequency among patients with liver fibrosis when compared to controls (OR (95% CI) 10.500 (2.086 – 52.851), P= 0.004 and 0.388 (0.155 – 0.971), P= 0.011), respectively. DEPDC5 rs1012068G allele variant showed statistically significant higher frequency among patients with liver fibrosis when compared to HCC patients (OR (95% CI) 3.316 (1.286 – 8.550), P= 0.012) and to both HCC and cirrhosis patients (OR (95% CI) 2.579 (1.187-5.645), P= 0.016). In conclusion, our results suggest that DEPDC5 rs1012068 G allele could be considered genetic risk allele for liver fibrosis and disease progression among Egyptian patients with chronic HCV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Disheveled EGL-10 and pleckstrin domain-containing 5 rs1012068 T/G gene polymorphism among Egyptian chronic HCV-infected patients: disease progression and related complications

Farhan

Abougabal

Gaber

et al. 2022

EJI

View full text Add to dashboard Cite

show abstract

“…Despite the emergence of DAAs, data on the risk of HCC post-DAA use is not well established. DAA-induced SVR mediated immunological changes and induced HBV reactivation, which did not impact HCC incidence [ 28 ]. Conti et al assumed that the high HCC risk post-DAAs was related to the severity of liver cirrhosis and previous HCC history rather than an HCV genotype or DAA regimen [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt

Sweed

Moaz

et al. 2022

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) remains a major health problem despite the emergence of several preventive and therapeutic modalities. HCC has heterogeneous and wide morpho-molecular patterns, resulting in unique clinical and prognostic criteria. Therefore, we aimed to study the clinical and pathological criteria of HCC to update the morpho-molecular classifications and provide a guide to the diagnosis of this disease. Methods Five hundred thirty pathologically analyzed HCC cases were included in this study. The clinical and survival data of these cases were collected. Results Hepatitis C virus is still the dominant cause of HCC in Egypt. Post-direct-acting antiviral agent HCC showed an aggressive course compared to interferon-related HCC. Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver were important prognostic parameters. Special HCC variants have characteristic clinical, laboratory, radiological, prognostic, and survival data. Tumor-infiltrating lymphocytes rather than neutrophil-rich HCC have an excellent prognosis. Conclusions HCC is a heterogenous tumor with diverse clinical, pathological, and prognostic parameters. Incorporating the clinicopathological profile per specific subtype is essential in the treatment decision of patients with HCC. Trial registration This was a retrospective study that included 530 HCC cases eligible for analysis. The cases were obtained from the archives of the Pathology Department, during the period between January 2010 and December 2019. Clinical and survival data were collected from the patients’ medical records after approval by the institutional review board (IRB No. 246/2021) of Liver National Institute, Menoufia University. The research followed the guidelines outlined in the Declaration of Helsinki and registered on ClinicalTrials.gov (NCT05047146).

show abstract

“…This might indicate that fibrosis regression has clinical implications. Cirrhosis regression was linked to lower morbidity and increased mortality in another HCV retrospective study[ 77 ]. However, there is currently a dearth of direct and convincing evidence that biopsy-proven fibrosis regression improves clinical outcomes.…”

Section: Effect Of Fibrosis Regression On Clinical Outcomesmentioning

confidence: 99%

Fibrosis regression following hepatitis C antiviral therapy

Elsharkawy¹,

Samir²,

El-Kassas³

2022

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is one of the most common causes of liver pathology. It is a major etiological factor of continuous liver injury by triggering an uncontrolled inflammatory response, causing liver fibrosis and cirrhosis. Liver fibrosis is a dynamic process that can be reversible upon timely cessation of the injurious agent, which in cases of HCV is represented by the sustained virological response (SVR) following antiviral therapies. Direct-acting antiviral therapy has recently revolutionized HCV therapy and minimized complications. Liver fibrosis can be assessed with variable invasive and non-invasive methods, with certain limitations. Despite the broad validation of the diagnostic and prognostic value of non-invasive modalities of assessment of liver fibrosis in patients with HCV, the proper interpretation of liver stiffness measurement in patients after SVR remains unclear. It is also still a debate whether this regression is caused by the resolution of liver injury following treatment of HCV, rather than true fibrosis regression. Regression of liver fibrosis can possess a positive impact on patient's quality of life reducing the incidence of complications. However, fibrosis regression does not abolish the risk of developing hepatocellular carcinoma, which mandates regular screening of patients with advanced fibrosis.

show abstract

Evaluation of HCV-related liver fibrosis post-successful DAA therapy

Cited by 6 publications

References 67 publications

Disheveled EGL-10 and pleckstrin domain-containing 5 rs1012068 T/G gene polymorphism among Egyptian chronic HCV-infected patients: disease progression and related complications

Disheveled EGL-10 and pleckstrin domain-containing 5 rs1012068 T/G gene polymorphism among Egyptian chronic HCV-infected patients: disease progression and related complications

The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt

Fibrosis regression following hepatitis C antiviral therapy

Contact Info

Product

Resources

About